Display options
Cite
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021;52:89-101doi: 10.1016/j.coviro.2021.11.012.
Pelletier, A. N., Sekaly, R. P., & Tomalka, J. A. (2021). Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Current opinion in virology, 5289-101. https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier, Adam N, et al. "Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines." Current opinion in virology vol. 52 (2021): 89-101. doi: https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10. PMID: 34902803; PMCID: PMC8664555.
Copy Download .nbib Format: NLM
Share it on

Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10.

Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.

Current opinion in virology

Adam N Pelletier, Rafick P Sekaly, Jeffrey A Tomalka

Affiliations

  1. RPM Bioinfo Solutions, Blainville, Quebec, Canada.
  2. Pathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  3. Pathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: [email protected].

PMID: 34902803 PMCID: PMC8664555 DOI: 10.1016/j.coviro.2021.11.012

Abstract

The SARS-CoV-2 pandemic has highlighted how an emergent disease can spread globally and how vaccines are once again the most important public health policy to combat infectious disease. Despite promising initial protection, the rise of new viral variants calls into question how effective current SARS-CoV-2 vaccines will be moving forward. Improving on vaccine platforms represents an opportunity to stay ahead of SARS-CoV-2 and keep the human population protected. Many researchers focus on modifying delivery platforms or altering the antigen(s) presented to improve the efficacy of the vaccines. Identifying mechanisms of natural immunity that result in the control of infection and prevent poor clinical outcomes provides an alternative approach to the development of efficacious vaccines. Early and current evidence shows that SARS-CoV-2 infection is marked by potent lung inflammation and relatively diminished antiviral signaling which leads to impaired immune recognition and viral clearance, essentially making SARS-CoV-2 'too hot to handle'.

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

References

  1. PLoS Pathog. 2020 Jul 29;16(7):e1008737 - PubMed
  2. Cell. 2021 Jul 22;184(15):3915-3935.e21 - PubMed
  3. Annu Rev Immunol. 2015;33:49-77 - PubMed
  4. J Exp Med. 2008 Dec 22;205(13):3119-31 - PubMed
  5. PLoS One. 2013 Jun 13;8(6):e65964 - PubMed
  6. Clin Chim Acta. 2020 Oct;509:91-94 - PubMed
  7. Cytokine Growth Factor Rev. 2020 Jun;53:13-24 - PubMed
  8. Cell. 2019 Sep 5;178(6):1313-1328.e13 - PubMed
  9. Nature. 2011 Sep 14;477(7366):596-600 - PubMed
  10. Lancet. 2021 Jan 9;397(10269):99-111 - PubMed
  11. Blood. 2020 Sep 3;136(10):1169-1179 - PubMed
  12. Sci Immunol. 2020 Jun 19;5(48): - PubMed
  13. N Engl J Med. 2021 Jun 10;384(23):2187-2201 - PubMed
  14. N Engl J Med. 2021 Aug 12;385(7):664-666 - PubMed
  15. Am J Emerg Med. 2020 Sep;38(9):1722-1726 - PubMed
  16. Eur J Immunol. 2010 Mar;40(3):616-9 - PubMed
  17. Mucosal Immunol. 2015 Nov;8(6):1226-36 - PubMed
  18. Nat Med. 2020 Jun;26(6):842-844 - PubMed
  19. J Control Release. 2018 Jan 28;270:1-13 - PubMed
  20. Nat Rev Immunol. 2020 Jul;20(7):397-398 - PubMed
  21. Immunity. 2011 Feb 25;34(2):213-23 - PubMed
  22. Front Immunol. 2021 Feb 18;11:622614 - PubMed
  23. N Engl J Med. 2021 Jun 10;384(23):2212-2218 - PubMed
  24. Respir Investig. 2020 Sep;58(5):419-420 - PubMed
  25. J Exp Med. 2021 Mar 1;218(3): - PubMed
  26. Front Immunol. 2020 May 15;11:1061 - PubMed
  27. J Biol Chem. 2008 Sep 19;283(38):25900-12 - PubMed
  28. Nature. 2021 Jun;594(7862):253-258 - PubMed
  29. J Immunol. 2008 Jul 1;181(1):17-21 - PubMed
  30. Clin Chim Acta. 2020 Oct;509:135-138 - PubMed
  31. Am J Pathol. 2004 Nov;165(5):1819-26 - PubMed
  32. Eur J Immunol. 2010 Dec;40(12):3528-34 - PubMed
  33. Int J Infect Dis. 2020 Jul;96:131-135 - PubMed
  34. Circ Res. 2016 Jan 8;118(1):145-56 - PubMed
  35. Nat Med. 2016 Jul;22(7):762-70 - PubMed
  36. Nat Immunol. 2021 Oct;22(10):1294-1305 - PubMed
  37. Nature. 2021 Aug;596(7872):410-416 - PubMed
  38. Inflamm Regen. 2020 Aug 6;40:19 - PubMed
  39. Front Immunol. 2020 Jul 10;11:1708 - PubMed
  40. FEBS J. 2016 Jan;283(1):9-24 - PubMed
  41. Nat Immunol. 2021 Jan;22(1):2-6 - PubMed
  42. J Exp Med. 2020 Dec 7;217(12): - PubMed
  43. Nature. 2016 Jul 06;535(7610):153-8 - PubMed
  44. J Med Virol. 2020 Nov;92(11):2409-2411 - PubMed
  45. Cell Host Microbe. 2021 Apr 14;29(4):516-521.e3 - PubMed
  46. Biochem J. 1995 Aug 15;310 ( Pt 1):143-8 - PubMed
  47. Nat Immunol. 2010 May;11(5):395-402 - PubMed
  48. Lancet Infect Dis. 2020 Oct;20(10):1135-1140 - PubMed
  49. Inflammation. 2008 Feb;31(1):36-46 - PubMed
  50. J Immunol. 2017 Jun 1;198(11):4383-4393 - PubMed
  51. Nat Immunol. 2021 Jan;22(1):32-40 - PubMed
  52. Cell Host Microbe. 2009 May 8;5(5):487-97 - PubMed
  53. Nature. 2008 Jun 19;453(7198):1122-6 - PubMed
  54. Eur J Immunol. 2016 Dec;46(12):2761-2766 - PubMed
  55. J Immunol. 2014 Feb 15;192(4):1587-96 - PubMed
  56. Nat Immunol. 2012 Jan 08;13(2):162-9 - PubMed
  57. Vaccine. 2016 Nov 11;34(47):5815-5818 - PubMed
  58. Lancet Infect Dis. 2021 Jan;21(1):39-51 - PubMed
  59. Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2562-7 - PubMed
  60. Sci Rep. 2021 Apr 13;11(1):8059 - PubMed
  61. PLoS Pathog. 2011 Dec;7(12):e1002379 - PubMed
  62. N Engl J Med. 2021 Feb 4;384(5):403-416 - PubMed
  63. J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331 - PubMed
  64. Nat Med. 2018 Jun;24(6):847-856 - PubMed
  65. Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):16059-64 - PubMed
  66. J Immunol. 2018 Jul 1;201(1):98-112 - PubMed
  67. Nat Rev Immunol. 2020 Jun;20(6):375-388 - PubMed
  68. Epidemiol Infect. 2020 Jul 09;148:e139 - PubMed
  69. J Infect. 2020 Sep;81(3):452-482 - PubMed
  70. Signal Transduct Target Ther. 2020 Mar 27;5(1):33 - PubMed
  71. J Med Virol. 2021 Dec;93(12):6468-6470 - PubMed
  72. Pharmaceutics. 2021 Jan 22;13(2): - PubMed
  73. J Immunol. 2012 Feb 15;188(4):1953-60 - PubMed
  74. Eur J Immunol. 2008 Aug;38(8):2085-9 - PubMed
  75. Mol Immunol. 2019 Mar;107:142-164 - PubMed
  76. Lancet Infect Dis. 2021 Sep 14;: - PubMed
  77. Immunity. 2017 Mar 21;46(3):393-404 - PubMed
  78. J Immunol. 2009 Oct 1;183(7):4403-14 - PubMed
  79. J Virol. 2011 Jan;85(1):146-55 - PubMed
  80. Antioxid Redox Signal. 2018 Oct 10;29(11):1023-1040 - PubMed
  81. Immunology. 2014 Feb;141(2):174-80 - PubMed
  82. Lancet Infect Dis. 2021 Feb;21(2):181-192 - PubMed
  83. Front Immunol. 2019 Nov 28;10:2791 - PubMed
  84. J Control Release. 2018 Jul 28;282:131-139 - PubMed
  85. Vaccines (Basel). 2013 Sep 25;1(4):415-43 - PubMed
  86. Cell. 2021 Apr 29;184(9):2523 - PubMed
  87. Immunity. 2009 Apr 17;30(4):576-87 - PubMed
  88. N Engl J Med. 2021 Aug 12;385(7):585-594 - PubMed
  89. Front Immunol. 2021 Oct 11;12:737487 - PubMed
  90. J Immunol. 2015 Jan 15;194(2):630-6 - PubMed
  91. Infect Drug Resist. 2020 Jul 22;13:2485-2493 - PubMed
  92. Nature. 2015 Oct 29;526(7575):660-5 - PubMed
  93. Sci Rep. 2016 Jan 21;6:19570 - PubMed
  94. Immunity. 2018 Mar 20;48(3):584-598.e5 - PubMed
  95. Cell. 2020 May 28;181(5):1036-1045.e9 - PubMed
  96. Nat Microbiol. 2020 May;5(5):688-696 - PubMed
  97. PLoS One. 2010 Apr 02;5(4):e10008 - PubMed
  98. EMBO Mol Med. 2021 Aug 9;13(8):e14150 - PubMed
  99. J Immunol. 2017 Nov 1;199(9):3293-3305 - PubMed
  100. Blood. 2009 Nov 5;114(19):4142-9 - PubMed
  101. J Clin Invest. 2015 Jun;125(6):2532-46 - PubMed
  102. Nat Immunol. 2006 Jun;7(6):576-82 - PubMed
  103. Int J Mol Sci. 2019 Jul 06;20(13): - PubMed
  104. Cell Death Discov. 2021 Mar 1;7(1):43 - PubMed
  105. J Intensive Care. 2020 May 24;8:36 - PubMed
  106. Lancet Respir Med. 2021 Feb;9(2):196-206 - PubMed
  107. N Engl J Med. 2021 May 20;384(20):1885-1898 - PubMed
  108. N Engl J Med. 2020 Dec 31;383(27):2603-2615 - PubMed
  109. Science. 2020 Aug 7;369(6504):718-724 - PubMed
  110. Immunol Rev. 2018 Jan;281(1):99-114 - PubMed
  111. SAGE Open Med. 2019 Mar 21;7:2050312119835043 - PubMed
  112. Science. 2021 Sep 17;373(6561):1372-1377 - PubMed
  113. Nature. 2020 Jul;583(7816):437-440 - PubMed
  114. Aging (Albany NY). 2020 Jun 24;12(12):11245-11258 - PubMed
  115. Front Immunol. 2019 Sep 27;10:2274 - PubMed

Publication Types